Literature DB >> 27006450

Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.

Reza Aghamohammadzadeh1, Ying-Yi Zhang1, Thomas E Stephens1, Elena Arons1, Paula Zaman1, Kevin J Polach2, Majed Matar2, Lai-Ming Yung1, Paul B Yu1, Frederick P Bowman1, Alexander R Opotowsky3, Aaron B Waxman4, Joseph Loscalzo1, Jane A Leopold1, Bradley A Maron5.   

Abstract

Activation of the mammalian target of rapamycin complex 1 (mTORC1) subunit Raptor induces cell growth and is a downstream target of Akt. Elevated levels of aldosterone activate Akt, and, in pulmonary arterial hypertension (PAH), correlate with pulmonary arteriole thickening, which suggests that mTORC1 regulation by aldosterone may mediate adverse pulmonary vascular remodeling. We hypothesized that aldosterone-Raptor signaling induces abnormal pulmonary artery smooth muscle cell (PASMC) survival patterns to promote PAH. Remodeled pulmonary arterioles from SU-5416/hypoxia-PAH rats and monocrotaline-PAH rats with hyperaldosteronism expressed increased levels of the Raptor target, p70S6K, which provided a basis for investigating aldosterone-Raptor signaling in human PASMCs. Aldosterone (10(-9) to 10(-7) M) increased Akt/mTOR/Raptor to activate p70S6K and increase proliferation, viability, and apoptosis resistance in PASMCs. In PASMCs transfected with Raptor-small interfering RNA or treated with spironolactone/eplerenone, aldosterone or pulmonary arterial plasma from patients with PAH failed to increase p70S6K activation or to induce cell survival in vitro Optimal inhibition of pulmonary arteriole Raptor was achieved by treatment with Staramine-monomethoxy polyethylene glycol that was formulated with Raptor-small interfering RNA plus spironolactone in vivo, which decreased arteriole muscularization and pulmonary hypertension in 2 experimental animal models of PAH in vivo Up-regulation of mTORC1 by aldosterone is a critical pathobiologic mechanism that controls PASMC survival to promote hypertrophic vascular remodeling and PAH.-Aghamohammadzadeh, R., Zhang, Y.-Y., Stephens, T. E., Arons, E., Zaman, P., Polach, K. J., Matar, M., Yung, L.-M., Yu, P. B., Bowman, F. P., Opotowsky, A. R., Waxman, A. B., Loscalzo, J., Leopold, J. A., Maron, B. A. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. © FASEB.

Entities:  

Keywords:  kinase signaling; pulmonary vascular disease; vascular remodeling

Mesh:

Substances:

Year:  2016        PMID: 27006450      PMCID: PMC4904292          DOI: 10.1096/fj.201500042

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  48 in total

1.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

2.  Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Authors:  Hans-Jürgen Seyfarth; Stefan Hammerschmidt; Michael Halank; Petra Neuhaus; Hubert R Wirtz
Journal:  Pulm Circ       Date:  2013-11-19       Impact factor: 3.017

3.  MicroRNA expression profile of pulmonary artery smooth muscle cells and the effect of let-7d in chronic thromboembolic pulmonary hypertension.

Authors:  Lei Wang; Li-Juan Guo; Jie Liu; Wang Wang; Jason X-J Yuan; Lan Zhao; Jun Wang; Chen Wang
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

4.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Authors:  M Sean McMurtry; Stephen L Archer; Dario C Altieri; Sebastien Bonnet; Alois Haromy; Gwyneth Harry; Sandra Bonnet; Lakshmi Puttagunta; Evangelos D Michelakis
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

5.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

6.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

7.  Purification and characterization of a novel ribosomal S6 kinase from skeletal muscle of insulin-treated rats.

Authors:  Y J Hei; S L Pelech; X Chen; J Diamond; J H McNeill
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

8.  Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice.

Authors:  Sachiko Sakurabayashi-Kitade; Yoshikazu Aoka; Hirotaka Nagashima; Hiroshi Kasanuki; Nobuhisa Hagiwara; Masatoshi Kawana
Journal:  Atherosclerosis       Date:  2009-02-07       Impact factor: 5.162

9.  The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.

Authors:  R B Pearson; P B Dennis; J W Han; N A Williamson; S C Kozma; R E Wettenhall; G Thomas
Journal:  EMBO J       Date:  1995-11-01       Impact factor: 11.598

10.  Wnt5a-induced Wnt1-inducible secreted protein-1 suppresses vascular smooth muscle cell apoptosis induced by oxidative stress.

Authors:  Carina Mill; Bethan Alice Monk; Helen Williams; Steven John Simmonds; Jamie Yancey Jeremy; Jason Lee Johnson; Sarah Jane George
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-11       Impact factor: 8.311

View more
  25 in total

1.  Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.

Authors:  Benjamin Strauss; Yassine Sassi; Carlos Bueno-Beti; Zeki Ilkan; Nour Raad; Marine Cacheux; Malik Bisserier; Irene C Turnbull; Erik Kohlbrenner; Roger J Hajjar; Lahouaria Hadri; Fadi G Akar
Journal:  J Mol Cell Cardiol       Date:  2018-11-28       Impact factor: 5.000

Review 2.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

3.  A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.

Authors:  Steven C Pugliese; Sushil Kumar; William J Janssen; Brian B Graham; Maria G Frid; Suzette R Riddle; Karim C El Kasmi; Kurt R Stenmark
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

Review 4.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

5.  mTORC1 Deficiency Modifies Volume Homeostatic Responses to Dietary Sodium in a Sex-Specific Manner.

Authors:  Danielle L Brooks; Amanda E Garza; Ezgi Caliskan Guzelce; Shadi K Gholami; Thitinan Treesaranuwattana; Stephen Maris; Sanjay Ranjit; Chee Sin Tay; Jessica M Lee; Jose R Romero; Gail K Adler; Luminita H Pojoga; Gordon H Williams
Journal:  Endocrinology       Date:  2020-05-01       Impact factor: 4.736

Review 6.  Emerging therapeutics in pulmonary hypertension.

Authors:  Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-01       Impact factor: 5.464

Review 7.  Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.

Authors:  Bradley A Maron; Jane A Leopold; Anna R Hemnes
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

8.  Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.

Authors:  Andressa Pena; Ahasanul Kobir; Dmitry Goncharov; Akiko Goda; Tatiana V Kudryashova; Arnab Ray; Rebecca Vanderpool; Jeffrey Baust; Baojun Chang; Ana L Mora; John Gorcsan; Elena A Goncharova
Journal:  Am J Respir Cell Mol Biol       Date:  2017-11       Impact factor: 6.914

9.  NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Authors:  Andriy O Samokhin; Thomas Stephens; Bradley M Wertheim; Rui-Sheng Wang; Sara O Vargas; Lai-Ming Yung; Minwei Cao; Marcel Brown; Elena Arons; Paul B Dieffenbach; Jason G Fewell; Majed Matar; Frederick P Bowman; Kathleen J Haley; George A Alba; Stefano M Marino; Rahul Kumar; Ivan O Rosas; Aaron B Waxman; William M Oldham; Dinesh Khanna; Brian B Graham; Sachiko Seo; Vadim N Gladyshev; Paul B Yu; Laura E Fredenburgh; Joseph Loscalzo; Jane A Leopold; Bradley A Maron
Journal:  Sci Transl Med       Date:  2018-06-13       Impact factor: 17.956

10.  IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium.

Authors:  Kai Peng; Xing Fan; Qiannan Li; Yiying Wang; Xiaolin Chen; Pingxi Xiao; Anthony G Passerini; Scott I Simon; ChongXiu Sun
Journal:  J Mol Cell Cardiol       Date:  2020-02-19       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.